Print Page  Close Window

2019 Press Releases

Keyword Search
 
DateTitle 
01/16/19New INGREZZA® (valbenazine) Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders
INGREZZA Significantly Reduced the Symptoms of Involuntary Movements in Patients with Bipolar or Major Depressive Disorder in Post-Hoc Analysis Patients Treated with INGREZZA Able to Remain on Existing Psychiatric Medications SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that a new analysis of INGREZZA® (valbenazine) capsules, published in the Journal of Affective Disorders1, demonstrated sustained improvement in tardive dyskinesia (TD... 
Printer Friendly Version
01/15/19Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2018 Financial Results
Conference Call and Webcast Scheduled for Tuesday, February 5 SAN DIEGO, Jan. 15, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2018 financial results after the Nasdaq market closes on Tuesday, Feb. 5, 2019. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). ... 
Printer Friendly Version
01/06/19Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2018 Net Product Sales Results and 2019 Program Milestones
- INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $130 Million with Approximately 22,900 TRx - INGREZZA® (valbenazine) Preliminary Full-Year 2018 Net Product Sales of Approximately $409 Million with Approximately 71,500 TRx SAN DIEGO, Jan. 6, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today provided an update on its business performance, including preliminary net product sales results for 2018, and key clinical development program... 
Printer Friendly Version
01/02/19Neurocrine Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
Live Audio Webcast will be on January 7, 2019 SAN DIEGO, Jan. 2, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 37th Annual J.P. Morgan Healthcare Conference at 2:30 p.m. PT (5:30 p.m. ET) on Monday, Jan. 7, 2019, in San Francisco. Kevin Gorman, Chief Executive Officer, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com.... 
Printer Friendly Version